Jamaica: the Socially Responsible Investment Solution
24.11.2022 19:25:00 EET | Business Wire | Press release
As efforts intensify to attract international investors to Jamaica’s shores, the Jamaican Government has redoubled its efforts to attract more Local and Foreign Direct Investments.
The upcoming two-day ‘Invest Jamaica – the Nearshore Delivery Hub of the Caribbean’ conference, set to be held in Montego Bay on 29-30 November, will continue to position Jamaica as the next global ‘investment destination of choice’, and is part of a five-year development project, in partnership with the Inter-American Development Bank (IDB), to expand the country’s Global Services Sector (GSS).
The event will highlight various innovative, mutually beneficial, and sustainable sector-based investment opportunities to potential investors from all over the world, particularly in the areas of Agribusiness, Global Digital Services, Logistics/Special Economic Zones, Manufacturing, Finance and Tourism.
Global Business Paired with Local Sustainability
The continued improvement of Jamaica’s economy will encourage a new wave of collaborative and multi-faceted investment in Jamaica which uniquely prioritizes sustainable projects deemed to be in both the national and global interest.
To assist with this bridging of the evolving needs of international investors and the local social development needs in Jamaica itself, a variety of both public and private sector initiatives are being rolled out ‘on the ground’ in the country. These initiatives include the National Investment Policy, Global Services Sector Project and the Business Environment Reforms Agenda. Importantly, these initiatives will give Jamaicans new career development opportunities and further strengthen the local economy, whilst enabling high-value skills development and offering an unprecedented level of support to investors.
The Holistic and Ethical Choice
Specifically, for the Global Service Sector (GSS) Project, the skills training and apprenticeship programmes will develop the Jamaican population in higher value-added service capabilities such as Management and Leadership, IT Infrastructure, Communication, Digital Marketing, Software Development and Integration, Critical and Analytical thinking, and human-centred Interaction Design.
Impressively, under the Apprenticeship Programme, close to 3,000 Jamaicans will be trained by the end of the GSS project, while under the High School Immersion Programme, 20,000 local students will be trained in enhanced job readiness and specialized tracks, creating monumental benefits for both Jamaica and its investors.
This type of thought-leading holistic and ethical approach to global business is transforming perceptions of global investment, and Jamaica is leading the charge.
Choose Jamaica. Invest in Jamaica.
More Information:
ABOUT JAMPRO
The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce. For more information on JAMPRO, please visit https://dobusinessjamaica.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221124005264/en/
Contact information
Amy Goulding
G&A Communications Inc
Tel: +1 246 820 8695
E-mail: amy@gacaribbean.com
JAMPRO
Jamaica Promotions Corporation
Marketing Communications
marketing@jamprocorp.com
(876) 978-7755
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom